Observations from a decade of oligonucleotide bioanalysis by LC-MS
There is a growing need for efficient bioanalysis of oligonucleotide therapeutics. This broad class of molecules presents numerous challenges relative to traditional small molecule therapeutics. Methodologies including ligand-binding assays or polymerase chain reaction may be fit-for-purpose in many instances, but liquid chromatography coupled to mass spectrometry (LC-MS) often delivers the best balance of sensitivity and selectivity. Over the last decade, we have engaged with many such molecules and derived insights into challenges and solutions. Herein, we provide four case studies illustrating challenges we have encountered. These issues include low or variable analyte recovery, poor resolution from related species, chromatographic abnormalities or challenging sensitivity. We present a summary of considerations, based on these experiences, to assist others working in the area.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Bioanalysis - (2024) vom: 18. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ewles, Matthew [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bioanalysis |
|---|
| Anmerkungen: |
Date Revised 18.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.4155/bio-2024-0007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371234646 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371234646 | ||
| 003 | DE-627 | ||
| 005 | 20240418234041.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240418s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2024-0007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1379.xml |
| 035 | |a (DE-627)NLM371234646 | ||
| 035 | |a (NLM)38634379 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ewles, Matthew |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Observations from a decade of oligonucleotide bioanalysis by LC-MS |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a There is a growing need for efficient bioanalysis of oligonucleotide therapeutics. This broad class of molecules presents numerous challenges relative to traditional small molecule therapeutics. Methodologies including ligand-binding assays or polymerase chain reaction may be fit-for-purpose in many instances, but liquid chromatography coupled to mass spectrometry (LC-MS) often delivers the best balance of sensitivity and selectivity. Over the last decade, we have engaged with many such molecules and derived insights into challenges and solutions. Herein, we provide four case studies illustrating challenges we have encountered. These issues include low or variable analyte recovery, poor resolution from related species, chromatographic abnormalities or challenging sensitivity. We present a summary of considerations, based on these experiences, to assist others working in the area | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a HRMS | |
| 650 | 4 | |a LC-MS | |
| 650 | 4 | |a bioanalysis | |
| 650 | 4 | |a chromatographic | |
| 650 | 4 | |a oligonucleotide | |
| 650 | 4 | |a perspective | |
| 650 | 4 | |a siRNA | |
| 650 | 4 | |a triple quadrupole | |
| 700 | 1 | |a Ledvina, Aaron R |e verfasserin |4 aut | |
| 700 | 1 | |a Powers, Brendan |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, C Eric |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d 2009 |g (2024) vom: 18. Apr. |w (DE-627)NLM196969840 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:18 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/bio-2024-0007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 18 |c 04 | ||